Quantcast
  Free Trial!
  Today’s Best Stocks To Trade!   
Click Here



Stocks

Trading Ideas

Short Term
Long Term
All Trading Ideas


Trading Lessons

Strategies
Courses
Interviews
Glossary
All Trading Lessons


Daily Stock Setups

Connors Daily Battle Plan
Haggerty Professional
Kaltbaum Intra-day Set-ups
Short Term PowerRatings
Long Term PowerRatings
TM Indicators


Trading News

Markets Updates
Technical Alerts
Breaking News


PowerRatings

Short Term
Long Term
Charts


Indicators

Stocks
Market Bias


Quotes

Markets
Stocks
Charts
Level II
Historical Data
Options


Trading Contests

Up or Down


 
The SI Report: Progressive Following on Enzon Pharmaceuticals Inc.
Thursday, April 10, 2008; Posted: 04:23 AM
Stocks RSS
Apr 10, 2008 (M2 PRESSWIRE via COMTEX) -- ENZN | news | PowerRating | PR Charts -- Streetinvesting.com has now resumed our progressive review of Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) as it opened up $0.05 on below average volume midday trading Wednesday, April 9, 2008. Based on the Company's most recent news release; we will be progressively reviewing the impact of the markets and the effects of their developments. We will be providing updates and analyst opinions as new stories unfold.

Make sure to visit www.streetinvesting.com to keep updated and signup for free with no credit card for market reports and analytical plays.

Our research resources have been aimed towards the US Large Caps and the various prospective companies therein Enzon Pharmaceuticals Inc. was among those that we have been closely examining due to their recent news and trading patterns. Sign up at www, streetinvesting.com for more information on the company mentioned herein.

April 9, 2008 -- Enzon Pharmaceuticals, Inc. will be presenting Inhibition of HIF-1alpha antagonist from in vitro and in vivo studies on Sunday, April 13, at the 2008 American Association for Cancer Research (AACR) meeting in San Diego, California.

On Monday, April 14, Enzon will host a cocktail reception from 6:30pm - 7:30pm in the Point Loma Room at the San Diego Marriott Hotel & Marina. This reception is an opportunity to hear some additional insight regarding Enzon's HIF-1alpha antagonist program.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar , DepoCyt , Abelcet and Adagen . The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

Streetinvesting.com will continue to follow the progress of this company following their most recent news announcement. Visit www.streetinvesting.com and signup free for our financial market services.

At Streetinvesting.com, we bring our knowledge of the marketplace and investment opportunities directly to our subscribers. As an aggressive-growth research company, our strength and goal is bringing distinctive trading opportunities and investment philosophies to investors seeking a different and unique approach to investment ideas. That's our goal. That's what we do. We are "The Word on the Street".

Let us become your number one portal for research and information on the global markets.

To continue with the more in-depth analysis, please visit www.streetinvesting.com for a complimentary subscription to access this report and other related articles. Please note that membership does not require credit card information.

All material herein was prepared by Streetinvesting.com, (Street Investing) based upon information believed to be reliable. The information contained herein is not guaranteed by Streetinvesting.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Streetinvesting.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Streetinvesting.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Streetinvesting.com's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.

Streetinvesting.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Streetinvesting.com undertakes no obligation to update such statements.

CONTACT: Streetinvesting.com WWW: http://www.streetinvesting.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Morning Coffee with TradingMarkets -- Free Newsletter

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Stocks RSS





PREMIER SPONSORED LINKS
TRADE CENTER

The TradingMarkets Directory
Stocks
Quotes
Charts
How to Trade
Commentary and Analysis
PowerRatings
Training Classes
Tools
Stock Scanner
Daily Market Bias

Options
Quotes
Charts
How to Trade
Commentary and Analysis

Forex
How to Trade
Forex Momentum Index
Pivots

E-mini/Futures
Quotes
Charts
How to Trade
Daily Market Bias

How to Trade
Stocks
Options
Forex
E-mini/Futures
Glossary

Tools
Short Term PowerRatings
Long Term PowerRatings
Stock Screener
Quotes & Charts
Stock Indicators
Market bias Indicators

PowerRatings
Short Term PowerRatings
Long Term PowerRatings
Industry PowerRatings
PowerRatings Charts
Training Classes
PowerRatings Strategies
Search PowerRatings

Trading Contests
Up or Down Stock Contest
#1 - Win $1000 every month

Up or Down Forex Contest -
Win $1000 every month


Premium Subscription Services
Short Term PowerRatings Free Trial
Long Term PowerRatings Free Trial
TradingMarkets Subscription Free Trial
Daily Battle Plan Free Trial
Gary Kaltbaum - Intraday Breaking Alerts Free Trial
Kevin Haggerty Professional Trading Service Free Trial
Forex Force with Mark Whistler Free Trial

RELATED SITES
Nothing but forex



All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2008 The Connors Group, Inc.